| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| GTO ID | GTC3152 |
| Trial ID | NCT05507827 |
| Disease | Lymphoid Leukemia |
| Altered gene | CD19|CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19/CD22 CAR-T cells |
| Generation | 2nd |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric Antigen Receptor) T Cells in Adults With B-cell Acute Lymphoblastic Leukemia (ALL) |
| Year | 2022 |
| Country | United States |
| Company sponsor | Crystal Mackall, MD |
| Other ID(s) | IRB-64357|NCI-2022-07232|BMT378 |
| Vector information | |||||
|
|||||
| Cohort 1 | |||||||||
|
|||||||||